Acute leukemia following prolonged cytotoxic agent therapy

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Acute non-lymphoblastic leukemia (ANLL) is a rare but serious complication of prolonged cytotoxic chemotherapy.
• Historically, ANLL was not observed in patients with lymphoproliferative disorders before the advent of chemotherapy.

Observation:

• Nine patients developed ANLL after prolonged alkylating agent therapy, with five receiving no radiotherapy.
• The underlying conditions included Hodgkin's disease, multiple myeloma, and other neoplasms, as well as non-neoplastic diseases.
• Over 125 reports of ANLL following cytotoxic therapy exist in the literature.

Findings:

• Alkylating agents are the predominant class of drugs associated with therapy-induced ANLL.
• More than half of ANLL patients received chemotherapy alone and experienced cytopenia and bone marrow dysplasia.
• Leukemia typically developed 3-5 years after the underlying disease diagnosis, following a median of 3.5 years of treatment.

Implications:

• The leukemogenic potential of prolonged cytotoxic therapy, especially alkylating agents, is well-established.
• This finding suggests caution against prolonged use of these agents in non-fatal conditions.
• Further controlled studies are needed to refine risk-benefit assessments and long-term therapy recommendations.